Atara Biotherapeutics (ATRA) Operating Expenses (2013 - 2026)

Atara Biotherapeutics (ATRA) has reported Operating Expenses for 14 consecutive years, with $5.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses fell 62.79% year-over-year to $5.4 million; the trailing twelve-month figure through Jun 2026 stood at $20.4 million (down 88.69% YoY), and the FY2025 full-year result was $84.9 million, down 60.02% from the prior year.
• Operating Expenses grew to $5.4 million in Q2 2026 per ATRA's latest filing, from $3.9 million in the prior quarter.
• Across five years, Operating Expenses topped out at $95.5 million in Q1 2022 and bottomed at $3.9 million in Q1 2026.
• Historically, Operating Expenses has averaged $52.0 million across 5 years, with a median of $60.6 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Operating Expenses advanced 16.79% in 2022, then tumbled 93.45% in 2026.
• Over 5 years, Operating Expenses stood at $75.8 million in 2022, then retreated by 15.24% to $64.2 million in 2023, then dropped by 29.99% to $45.0 million in 2024, then sank by 90.75% to $4.2 million in 2025, then grew by 28.67% to $5.4 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $5.4 million, $3.9 million, and $4.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.